Ticker Details
BioCryst Pharmaceuticals, Inc. Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases.
IPO Date:	March 4, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.85B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.21 | 3.03%
Avg Daily Range (30 D):	$0.15 | 2.20%
Avg Daily Range (90 D):	$0.14 | 1.96%

Institutional Daily Volume
Avg Daily Volume:	1.59M
Avg Daily Volume (30 D):	3.71M
Avg Daily Volume (90 D):	4.27M

Trade Size
Avg Trade Size (Sh.):	178
Avg Trade Size (Sh.) (30 D):	154
Avg Trade Size (Sh.) (90 D):	155

Institutional Trades
Total Institutional Trades:	4,027
Avg Institutional Trade:	$2.26M
Avg Institutional Trade (30 D):	$3.22M
Avg Institutional Trade (90 D):	$2.34M
Avg Institutional Trade Volume:	.28M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.13M
Avg Closing Trade (30 D):	$3.85M
Avg Closing Trade (90 D):	$3.58M
Avg Closing Volume:	383.96K

News

Feb 11, 2026 @ 12:00 PM BioCryst to Present New HAE Data from ORLADEYO®... Source: Biocryst Pharmaceuticals, Inc.

Jan 23, 2026 @ 2:00 PM BioCryst Completes Acquisition of Astria Therapeut... Source: Na

Nov 22, 2025 @ 10:41 AM Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareho... Source: Halper Sadeh Llc

Oct 23, 2025 @ 11:00 AM BioCryst to Present New Pediatric HAE Data at the ... Source: Biocryst Pharmaceuticals

Oct 14, 2025 @ 4:20 PM BioCryst Says Astria Therapeutics $700 Million Dea... Source: Vandana Singh

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.05	$.06	$.02
Diluted EPS	$-.05	$.06	$.02
Revenue	$599.82M	$159.4M	$163.35M
Gross Profit	$584.17M	$157.21M	$160.56M
Net Income / Loss	$-8.78M	$12.9M	$5.09M
Operating Income / Loss	$76.1M	$29.59M	$29.79M
Cost of Revenue	$15.65M	$2.19M	$2.8M
Net Cash Flow	$1.83M	$-4.09M	$-1.9M
PE Ratio